How To Accelerate Development In Novel & Advanced Oncology Therapies — From The Starting Line

In what ways is the industry innovating CAR-T, ADCs, Immunotherapies, and mRNAs as they wind their way through the pipeline and beyond? How can teams set up trials with the end game in mind? What are the key considerations to accelerate oncology clinical development timelines to support a global program strategy?

Moderated by Founder and Publisher of Endpoints News Arsalan Arif, hear from the following panelists on how to dissect the shift in early-phase oncology design with a particular focus on Bayesian Data:

• Vishal Navani, Staff Medical Oncologist, Professor, Tom Baker Cancer Centre, University of Calgary
• Kedan Lin, Senior Vice President, Harbour Biomed
• Michele Gerber, Chief Medical Officer, Myeloid Therapeutics
• Jayesh Desai, Professor, Medical Oncologist/Clinical Research Head, Early Drug Development, Peter MacCallum Cancer Centre
• Patricia Mucci LoRusso, Director – Early Phase Clinical Trials Program, Associate Center Director – Experimental Therapeutics, Yale Cancer Center/Yale University